IP Library › Granted Patent US 12,458,427
Granted Patent B2
US 12,458,427 · App. 17/357,720 · Granted Nov 4, 2025

Multi-pole synchronous pulmonary artery radiofrequency ablation catheter

Inventor: Shaoliang Chen (Nanjing, CN)
Assignee: Pulnovo Medical (Wuxi) Co., Ltd.
A61B18/1206A61B18/1492A61N1/06A61B2017/00867A61B2017/320069A61B2018/00029A61B2018/00345A61B2018/00357A61B2018/00375A61B2018/00404A61B2018/00434A61B2018/00577A61B2018/00613A61B2018/00642A61B2018/00702A61B2018/00791A61B2018/00797A61B2018/00916A61B2018/00988A61B2018/124A61B2018/1407A61B2018/144A61B2018/1467A61B2218/002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,458,427
App. No.
17/357,720
Granted
Nov 4, 2025
Kind
B2
Abstract

A multi-pole synchronous pulmonary artery radiofrequency ablation catheter may comprise a control handle, a catheter body and an annular ring. One end of the catheter body may be flexible, and the flexible end of the catheter body may be connected to the annular ring. The other end of the catheter body may be connected to the control handle. A shape memory wire may be arranged in the annular ring. One end of the shape memory wire may extend to an end of the annular ring and the other end of the shape memory wire may pass through a root of the annular ring and be fixed on the flexible end of the catheter body. The annular ring may be provided with an electrode group. The device possesses advantages of simple operation, short operation time and controllable precise ablation. The device can be used to treat pulmonary hypertension with pulmonary denervation.

Claims (43)

1 . A method of performing pulmonary artery denervation, said method comprising:

(a) providing an ablation device to a user;

(b) providing computer executable instructions to the ablation device to:

(i) ablate target tissue in a pulmonary artery trunk under conditions effective to affect a reduction in mean pulmonary artery pressure of the patient when at least one ablation element of the ablation device is positioned within or in proximity to the pulmonary artery trunk of a patient, the pulmonary artery trunk including a distal portion of a main pulmonary artery, a proximal portion of a left pulmonary artery, and a proximal portion of a right pulmonary artery,

wherein the target tissue is in a portion of the pulmonary artery trunk proximal to a left side lateral wall at the distal portion of the main pulmonary artery and proximal to a lower wall of the proximal portion of the left pulmonary artery, and

wherein the conditions effective to affect the reduction in mean pulmonary artery pressure also affect a reduction in systolic pulmonary artery pressure, and

(ii) modify at least one ablation parameter for ablation of the target tissue in response to feedback from at least one sensor of the ablation device; and

(c) subsequent to (b), ablating the target tissue with the ablation device.

2 . The method of claim 1 , wherein the reduction in mean pulmonary artery pressure is about 15%.

3 . The method of claim 1 , wherein the reduction in mean pulmonary artery pressure is about 25%.

4 . The method of claim 1 , wherein the reduction in systolic pulmonary artery pressure is about 15%.

5 . The method of claim 1 , wherein the reduction in systolic pulmonary artery pressure is about 20%.

6 . The method of claim 1 , wherein the conditions effective to affect the reduction in mean pulmonary artery pressure also affect an in increase in 6-minute walk distance (6MWD).

7 . The method of claim 6 , wherein the increase in the 6MWD is about 25%.

8 . The method of claim 1 , wherein the computer executable instructions to the ablation device are provided for the ablation device to ablate the target tissue at a temperature of about 50° degrees C. to about 60° degrees C.

9 . The method of claim 1 , wherein the computer executable instructions to the ablation device are provided for the ablation device to ablate the target tissue with an energy of between about 3 W to about 15 W.

10 . The method of claim 1 , wherein the computer executable instructions to the ablation device are provided for the ablation device to ablates the target tissue for between about 60 and about 120 seconds.

11 . The method of claim 1 , wherein the computer executable instructions to the ablation device are provided for the ablation device to ablate the target tissue with at least one of radiofrequency (RF) energy, microwave energy, ultrasound energy, focused ultrasound energy, ionizing energy, electroporation, a drug, a chemical agent, or cryoablation.

12 . The method of claim 1 , wherein in (c), ablating the target tissue causes disruption of sympathetic nerves at the pulmonary artery trunk.

13 . The method of claim 1 , wherein in (c), ablating the target tissue comprising ablating the target tissue with a continuous ablation pattern.

14 . The method of claim 1 , wherein in (c), ablating the target tissue comprises ablating the target tissue with a non-continuous ablation pattern.

15 . The method of claim 1 , wherein the ablation element of the ablation device is a distal elliptical ring which is positioned adjacent the target tissue.

16 . The method of claim 15 , wherein-a handle of the ablation device is one or more of rotated or pushed to position the distal elliptical ring adjacent the target tissue.

17 . The method of claim 15 , wherein in (c), ablating the target tissue comprises ablating the target tissue with the distal elliptical ring positioned adjacent the target tissue, the distal elliptical ring comprising the at least one ablation element, the at least one ablation element comprising one or more ablation electrodes.

18 . The method of claim 17 , wherein the one or more ablation electrodes comprises first, second, and third ablation electrodes.

19 . The method of claim 18 , wherein in (c), ablating the target tissue comprises ablating one or more of a first ablation site at a left lateral apex of the distal portion of the main pulmonary artery with the first ablation electrode, a second ablation site at an anterior side of the left lateral apex of the distal portion of the main pulmonary artery, or a third ablation site at a posterior side of the left lateral apex of the distal portion of the main pulmonary artery with the third electrode.

20 . The method of claim 19 , wherein in (c), ablating the target tissue comprises ablating two or more of the first, second, or third ablation sites.

21 . The method of claim 20 , wherein in (c), ablating the target tissue comprises ablating each of the first, second, and third ablation sites.

22 . The method of claim 17 , wherein the one or more ablation electrodes are positioned to straddle an apex of a major axis of the distal elliptical ring.

23 . The method of claim 1 , wherein the user advances the ablation device into a femoral vein of the patient, upwardly into an inferior vena cava of the patient, then upwards into a right atrium of the patient, then down into a right ventricle of the patient, and then up through a pulmonary semilunar valve of the patient to the main pulmonary artery trunk.

24 . The method of claim 1 , wherein the computer executable instructions to the ablation device further comprises computer executable instructions for the ablation device to provide to the user visualization of at least one of the main pulmonary artery trunk or the ablation device positioned in the main pulmonary artery trunk to confirm positioning of the ablation device.

25 . The method of claim 1 , wherein the user visualizes the main pulmonary artery prior to positioning the ablation device in the pulmonary artery trunk.

26 . The method of claim 1 , wherein the user visualizes the main pulmonary artery with one or more of magnetic resonance imaging (MRI) or computed tomography (CT) scanning.

27 . The method of claim 1 , further comprising the user withdrawing the ablation device from the main pulmonary artery after the target tissue has been ablated.

28 . The method of claim 27 , further comprising the user visualizing the main pulmonary artery after the ablation device has been withdrawn.

29 . The method of claim 1 , wherein in (c), ablating the target tissue comprises ablating a first ablation site at a left lateral apex of the distal portion of the main pulmonary artery.

30 . The method of claim 29 , wherein ablating the target tissue comprises ablating one or more of a second ablation site at an anterior side of the left lateral apex of the distal portion of the main pulmonary artery or a third ablation site at a posterior side of the left lateral apex of the distal portion of the main pulmonary artery.

31 . The method of claim 30 , wherein ablating the target tissue comprises ablating ablates each of the first, second, and third ablation sites.

32 . The method of claim 1 , wherein the computer executable instructions comprise configuring one or more computer systems to perform operations comprising receiving a selection of a first patient profile of a plurality of stored patient profiles from a user interface presented on an electronic display.

33 . The method of claim 1 , wherein the at least one sensor measures temperature, impedance, or both of the target tissue.

34 . The method of claim 33 , wherein the at least one ablation parameter is modified based on the measured temperature, impedance, or both of the target tissue.

35 . The method of claim 1 , wherein the at least one ablation parameter comprises one or more of target temperature, power, or ablation time.

36 . The method of claim 1 , wherein the at least one sensor provides the feedback in real-time.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2026
From: PULNOVO MEDICAL (WUXI) CO., LTD.
To: PULNOVO MEDICAL INC.
Reel/Frame 073758/0501 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 5661 FRAME: 910. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jul 31, 2025
From: CHEN, SHAOLIANG
To: PULNOVO MEDICAL (WUXI) CO., LTD.
Reel/Frame 072312/0866 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2021
From: CHEN, SHAOLIANG
To: PULNOVO MEDICAL (WUXI) CO., LTD
Reel/Frame 056661/0910 →
Priority Claims (2)
CN 201210453470.4 · Nov 13, 2012 · national
CN 201310103141.1 · Mar 27, 2013 · national
Continuity (7)
Continuation 15873721 · Jan 17, 2018
Continuation 14672013 · Mar 27, 2015
Continuation 14666214 · Mar 23, 2015
Continuation In Part 14530588 · Oct 31, 2014
Continuation In Part 14079230 · Nov 13, 2013
Provisional Application 62023781 · Jul 11, 2014
Related Publication 20210338305A1 · Nov 4, 2021
References Cited (400)
US 5263493A · Avitall · 1993 [cited by applicant]
US 5643197A · Brucker et al. · 1997 [cited by applicant]
US 5715817A · Stevens-Wright et al. · 1998 [cited by applicant]
US 5782900A · de La Rama et al. · 1998 [cited by applicant]
US 5797905A · Fleischman et al. · 1998 [cited by applicant]
US 5830214A · Flom et al. · 1998 [cited by applicant]
US 5833604A · Houser et al. · 1998 [cited by applicant]
US 5836947A · Fleischman et al. · 1998 [cited by applicant]
US 5913856A · Chia et al. · 1999 [cited by applicant]
US 5919188A · Shearon et al. · 1999 [cited by applicant]
US 5938694A · Jaraczewski et al. · 1999 [cited by applicant]
US 6064902A · Haissaguerre et al. · 2000 [cited by applicant]
US 6090104A · Webster, Jr. · 2000 [cited by applicant]
US 6096036A · Bowe et al. · 2000 [cited by applicant]
US 6115626A · Whayne et al. · 2000 [cited by applicant]
US 6123702A · Swanson et al. · 2000 [cited by applicant]
US 6198974B1 · Webster, Jr. · 2001 [cited by applicant]
US 6237886B1 · Katsumata et al. · 2001 [cited by applicant]
US 6292695B1 · Webster, Jr. et al. · 2001 [cited by applicant]
US 6411852B1 · Danek et al. · 2002 [cited by applicant]
US 6493589B1 · Medhkour et al. · 2002 [cited by applicant]
US 6532378B2 · Saksena et al. · 2003 [cited by applicant]
US 6564096B2 · Mest · 2003 [cited by applicant]
US 6575969B1 · Rittman, III et al. · 2003 [cited by applicant]
US 6690971B2 · Schauerte et al. · 2004 [cited by applicant]
US 7260431B2 · Libbus et al. · 2007 [cited by applicant]
US 7269457B2 · Shafer et al. · 2007 [cited by applicant]
US 7363076B2 · Yun et al. · 2008 [cited by applicant]
US 7367951B2 · Bennett et al. · 2008 [cited by applicant]
US 7587238B2 · Moffitt et al. · 2009 [cited by applicant]
US 7616990B2 · Chavan et al. · 2009 [cited by applicant]
US 7623926B2 · Rossing et al. · 2009 [cited by applicant]
US 7630760B2 · Libbus et al. · 2009 [cited by applicant]
US 7660628B2 · Libbus et al. · 2010 [cited by applicant]
US 7664548B2 · Amurthur et al. · 2010 [cited by applicant]
US 7711430B2 · Errico et al. · 2010 [cited by applicant]
US 7715915B1 · Ryu et al. · 2010 [cited by applicant]
US 7734355B2 · Cohen et al. · 2010 [cited by applicant]
US 7744618B2 · Shuros et al. · 2010 [cited by applicant]
US 7783353B2 · Libbus et al. · 2010 [cited by applicant]
US 7789877B2 · Vanney · 2010 [cited by applicant]
US 7801604B2 · Brockway et al. · 2010 [cited by applicant]
US 7826899B1 · Ryu et al. · 2010 [cited by applicant]
US 7828795B2 · Privitera et al. · 2010 [cited by applicant]
US 7899527B2 · Yun et al. · 2011 [cited by applicant]
US 7925342B2 · Amurthur et al. · 2011 [cited by applicant]
US 7937147B2 · Sih et al. · 2011 [cited by applicant]
US 8019435B2 · Hastings et al. · 2011 [cited by applicant]
US 8027724B2 · Wei et al. · 2011 [cited by applicant]
US 8032215B2 · Libbus et al. · 2011 [cited by applicant]
US 8052668B2 · Sih · 2011 [cited by applicant]
US 8073538B2 · Peters et al. · 2011 [cited by applicant]
US 8088127B2 · Mayse et al. · 2012 [cited by applicant]
US 8116883B2 · Williams et al. · 2012 [cited by applicant]
US 8126559B2 · Libbus · 2012 [cited by applicant]
US 8229564B2 · Rezai · 2012 [cited by applicant]
US 8249705B1 · Kieval et al. · 2012 [cited by applicant]
US 8369954B2 · Stack et al. · 2013 [cited by applicant]
US 8442638B2 · Libbus et al. · 2013 [cited by applicant]
US 8483832B2 · Simon · 2013 [cited by applicant]
US 8527064B2 · Zhang et al. · 2013 [cited by applicant]
US 8585601B2 · Sverdlik et al. · 2013 [cited by applicant]
US 8620400B2 · De La Rama et al. · 2013 [cited by applicant]
US 8652201B2 · Oberti et al. · 2014 [cited by applicant]
US 8672917B2 · Sigg et al. · 2014 [cited by applicant]
US 8696581B2 · Sverdlik et al. · 2014 [cited by applicant]
US 8702619B2 · Wang · 2014 [cited by applicant]
US 8808345B2 · Clark et al. · 2014 [cited by applicant]
US 8840601B2 · Salahieh et al. · 2014 [cited by applicant]
US 8911439B2 · Mayse et al. · 2014 [cited by applicant]
US 8929990B2 · Moffitt et al. · 2015 [cited by applicant]
US 8983609B2 · Rezai et al. · 2015 [cited by applicant]
US 8986231B2 · Gertner et al. · 2015 [cited by applicant]
US 9005100B2 · Gnanashanmugam et al. · 2015 [cited by applicant]
US 9023034B2 · Jenson et al. · 2015 [cited by applicant]
US 9028391B2 · Gnanashanmugam et al. · 2015 [cited by applicant]
US 9028417B2 · Sverdlik et al. · 2015 [cited by applicant]
US 9028485B2 · Edmunds et al. · 2015 [cited by applicant]
US 9072894B2 · Chin et al. · 2015 [cited by applicant]
US 9084609B2 · Smith · 2015 [cited by applicant]
US 9089350B2 · Willard · 2015 [cited by applicant]
US 9126044B2 · Kramer et al. · 2015 [cited by applicant]
US 9283031B2 · Janssen et al. · 2016 [cited by applicant]
US 9326786B2 · Sverdlik et al. · 2016 [cited by applicant]
US 9345900B2 · Wu et al. · 2016 [cited by applicant]
US 9427277B2 · Swanson et al. · 2016 [cited by applicant]
US 9522035B2 · Highsmith · 2016 [cited by applicant]
US 9566456B2 · Sverdlik et al. · 2017 [cited by applicant]
US 9649153B2 · Mayse et al. · 2017 [cited by applicant]
US 9820800B2 · Chen · 2017 [cited by applicant]
US 9827036B2 · Chen · 2017 [cited by applicant]
US 9833623B2 · Gnanashanmugam et al. · 2017 [cited by applicant]
US 9872720B2 · Chen · 2018 [cited by applicant]
US 9918776B2 · Chen · 2018 [cited by applicant]
US 10357304B2 · Sverdlik et al. · 2019 [cited by applicant]
US 10368893B2 · Sverdlik et al. · 2019 [cited by applicant]
US 10518112B2 · Gilad · 2019 [cited by applicant]
US 10874454B2 · Chen · 2020 [cited by applicant]
US 10933259B2 · Sverdlik et al. · 2021 [cited by applicant]
US 10946197B2 · Yun et al. · 2021 [cited by applicant]
US 10967160B2 · Sverdlik et al. · 2021 [cited by applicant]
US 11007001B1 · Carignan et al. · 2021 [cited by applicant]
US 11241267B2 · Chen · 2022 [cited by applicant]
US 11318331B2 · Shabtay et al. · 2022 [cited by applicant]
US 11357447B2 · Sverdlik et al. · 2022 [cited by applicant]
US 11395694B2 · Hata et al. · 2022 [cited by applicant]
US 11534631B2 · Gilad · 2022 [cited by applicant]
US 11717346B2 · Grasse et al. · 2023 [cited by applicant]
US 12082868B2 · Chen · 2024 [cited by applicant]
US 20010020166A1 · Daly et al. · 2001 [cited by applicant]
US 20010031987A1 · Saksena et al. · 2001 [cited by applicant]
US 20020058933A1 · Christopherson et al. · 2002 [cited by applicant]
US 20020065514A1 · Rashidi · 2002 [cited by applicant]
US 20020120304A1 · Mest · 2002 [cited by applicant]
US 20040133197A1 · Utley et al. · 2004 [cited by applicant]
US 20050004440A1 · Vanney · 2005 [cited by applicant]
US 20050004565A1 · Vanney · 2005 [cited by applicant]
US 20050010095A1 · Stewart et al. · 2005 [cited by applicant]
US 20050113822A1 · Fuimaono et al. · 2005 [cited by applicant]
US 20050153885A1 · Yun et al. · 2005 [cited by applicant]
US 20050261672A1 · Deem et al. · 2005 [cited by applicant]
US 20050283148A1 · Janssen et al. · 2005 [cited by applicant]
US 20060041277A1 · Deem et al. · 2006 [cited by applicant]
US 20060074272A1 · Diubaldi · 2006 [cited by applicant]
US 20060116737A1 · Libbus · 2006 [cited by applicant]
US 20060167498A1 · Dilorenzo · 2006 [cited by applicant]
US 20060217772A1 · Libbus et al. · 2006 [cited by applicant]
US 20060241366A1 · Falwell et al. · 2006 [cited by applicant]
US 20070032835A1 · Rittman et al. · 2007 [cited by applicant]
US 20070038055A1 · Fuimaono et al. · 2007 [cited by applicant]
US 20070060921A1 · Janssen et al. · 2007 [cited by applicant]
US 20070083193A1 · Werneth et al. · 2007 [cited by applicant]
US 20070083194A1 · Kunis et al. · 2007 [cited by applicant]
US 20070129720A1 · Demarais et al. · 2007 [cited by applicant]
US 20070129760A1 · Demarais et al. · 2007 [cited by applicant]
US 20070142879A1 · Greenberg et al. · 2007 [cited by applicant]
US 20070191904A1 · Libbus et al. · 2007 [cited by applicant]
US 20070225641A1 · Schneider et al. · 2007 [cited by applicant]
US 20070255379A1 · Williams et al. · 2007 [cited by applicant]
US 20080255642A1 · Zarins et al. · 2008 [cited by applicant]
US 20080281312A1 · Werneth et al. · 2008 [cited by applicant]
US 20080306570A1 · Rezai et al. · 2008 [cited by applicant]
US 20090024124A1 · Lefler et al. · 2009 [cited by applicant]
US 20090062873A1 · Wu et al. · 2009 [cited by applicant]
US 20090118780A1 · Dilorenzo · 2009 [cited by applicant]
US 20090177262A1 · Oberti et al. · 2009 [cited by applicant]
US 20090216290A1 · Ruse et al. · 2009 [cited by applicant]
US 20090228078A1 · Zhang et al. · 2009 [cited by applicant]
US 20090248119A1 · Libbus et al. · 2009 [cited by applicant]
US 20090254142A1 · Edwards et al. · 2009 [cited by applicant]
US 20100057074A1 · Roman et al. · 2010 [cited by applicant]
US 20100094196A1 · Nash et al. · 2010 [cited by applicant]
US 20100113928A1 · Thapliyal et al. · 2010 [cited by applicant]
US 20100114095A1 · Janssen et al. · 2010 [cited by applicant]
US 20100137860A1 · Demarais et al. · 2010 [cited by applicant]
US 20100152726A1 · Cadouri et al. · 2010 [cited by applicant]
US 20100168548A1 · Govari et al. · 2010 [cited by applicant]
US 20100217347A1 · Swoyer et al. · 2010 [cited by applicant]
US 20100222859A1 · Govari et al. · 2010 [cited by applicant]
US 20100228317A1 · Libbus et al. · 2010 [cited by applicant]
US 20100241188A1 · Errico et al. · 2010 [cited by applicant]
US 20100249568A1 · Stehr et al. · 2010 [cited by applicant]
US 20100249773A1 · Clark et al. · 2010 [cited by applicant]
US 20100249859A1 · Dilorenzo · 2010 [cited by applicant]
US 20100268307A1 · Demarais et al. · 2010 [cited by applicant]
US 20100274221A1 · Sigg et al. · 2010 [cited by applicant]
US 20100286684A1 · Hata et al. · 2010 [cited by applicant]
US 20100286734A1 · Yun et al. · 2010 [cited by applicant]
US 20100298905A1 · Simon · 2010 [cited by applicant]
US 20110034915A1 · Ibrahim et al. · 2011 [cited by applicant]
US 20110082537A1 · Moffitt et al. · 2011 [cited by applicant]
US 20110112400A1 · Emery et al. · 2011 [cited by applicant]
US 20110118725A1 · Mayse et al. · 2011 [cited by applicant]
US 20110152855A1 · Mayse et al. · 2011 [cited by applicant]
US 20110160720A1 · Johnson · 2011 [cited by applicant]
US 20110166482A1 · Stack et al. · 2011 [cited by applicant]
US 20110178569A1 · Parnis et al. · 2011 [cited by applicant]
US 20110200171A1 · Beetel et al. · 2011 [cited by applicant]
US 20110202098A1 · Demarais et al. · 2011 [cited by applicant]
US 20110207758A1 · Sobotka et al. · 2011 [cited by applicant]
US 20110257561A1 · Gertner et al. · 2011 [cited by applicant]
US 20110257622A1 · Salahieh et al. · 2011 [cited by applicant]
US 20110257708A1 · Kramer et al. · 2011 [cited by applicant]
US 20110276103A1 · Maile et al. · 2011 [cited by applicant]
US 20110301587A1 · Deem et al. · 2011 [cited by applicant]
US 20110301664A1 · Rezai · 2011 [cited by applicant]
US 20110301679A1 · Rezai et al. · 2011 [cited by applicant]
US 20110306851A1 · Wang · 2011 [cited by applicant]
US 20120029505A1 · Jenson · 2012 [cited by applicant]
US 20120029509A1 · Smith · 2012 [cited by applicant]
US 20120029510A1 · Haverkost · 2012 [cited by applicant]
US 20120029511A1 · Smith et al. · 2012 [cited by applicant]
US 20120029512A1 · Willard et al. · 2012 [cited by applicant]
US 20120065554A1 · Pikus · 2012 [cited by applicant]
US 20120078129A1 · Bailin · 2012 [cited by applicant]
US 20120095371A1 · Sverdlik et al. · 2012 [cited by applicant]
US 20120116382A1 · Ku et al. · 2012 [cited by applicant]
US 20120123258A1 · Willard · 2012 [cited by applicant]
US 20120123406A1 · Edmunds et al. · 2012 [cited by applicant]
US 20120143294A1 · Clark et al. · 2012 [cited by applicant]
US 20120157992A1 · Smith et al. · 2012 [cited by applicant]
US 20120157993A1 · Jenson et al. · 2012 [cited by applicant]
US 20120158104A1 · Huynh et al. · 2012 [cited by applicant]
US 20120165815A1 · Collins et al. · 2012 [cited by applicant]
US 20120172680A1 · Gelfand et al. · 2012 [cited by applicant]
US 20120172870A1 · Jenson et al. · 2012 [cited by applicant]
US 20120184952A1 · Jenson et al. · 2012 [cited by applicant]
US 20120215106A1 · Sverdlik et al. · 2012 [cited by applicant]
US 20120232551A1 · Swanson et al. · 2012 [cited by applicant]
US 20120272839A1 · Kaneko · 2012 [cited by applicant]
US 20120277839A1 · Kramer et al. · 2012 [cited by applicant]
US 20120290024A1 · Zhang et al. · 2012 [cited by applicant]
US 20120294424A1 · Chin et al. · 2012 [cited by applicant]
US 20120302909A1 · Mayse et al. · 2012 [cited by applicant]
US 20130110104A1 · Corvi et al. · 2013 [cited by applicant]
US 20130131743A1 · Yamasaki et al. · 2013 [cited by applicant]
US 20130165922A1 · Falwell et al. · 2013 [cited by applicant]
US 20130204068A1 · Gnanashanmugam et al. · 2013 [cited by applicant]
US 20130204242A1 · Sverdlik et al. · 2013 [cited by applicant]
US 20130211396A1 · Sverdlik et al. · 2013 [cited by applicant]
US 20130211437A1 · Sverdlik et al. · 2013 [cited by applicant]
US 20130218054A1 · Sverdlik et al. · 2013 [cited by applicant]
US 20130218068A1 · Sverdlik et al. · 2013 [cited by applicant]
US 20130317375A1 · Garcia et al. · 2013 [cited by applicant]
US 20140179993A1 · Alexander et al. · 2014 [cited by applicant]
US 20140180277A1 · Chen · 2014 [cited by applicant]
US 20140187894A1 · Bui et al. · 2014 [cited by applicant]
US 20150057599A1 · Chen · 2015 [cited by applicant]
US 20160128767A1 · Azamian et al. · 2016 [cited by applicant]
US 20180326227A1 · Sverdlik et al. · 2018 [cited by applicant]
US 20190290350A1 · Sverdlik et al. · 2019 [cited by applicant]
US 20190308003A1 · Sverdlik et al. · 2019 [cited by applicant]
US 20190366130A1 · Sverdlik et al. · 2019 [cited by applicant]
US 20200238107A1 · Shabtay et al. · 2020 [cited by applicant]
US 20210178194A1 · Sverdlik et al. · 2021 [cited by applicant]
US 20220241617A1 · Shabtay et al. · 2022 [cited by applicant]
US 20220287634A1 · Sverdlik et al. · 2022 [cited by applicant]
US 20230037695A1 · Carignan et al. · 2023 [cited by applicant]
US 20230380881A1 · Chen · 2023 [cited by applicant]
AU 2007290727B2 · 2012 [cited by applicant]
AU 2015287691B2 · 2019 [cited by applicant]
AU 2019204804B2 · 2020 [cited by applicant]
CN 101797181A · 2010 [cited by applicant]
CN 102119009A · 2011 [cited by applicant]
CN 102198015A · 2011 [cited by applicant]
CN 102641153A · 2012 [cited by applicant]
CN 102686179A · 2012 [cited by applicant]
CN 102908191A · 2013 [cited by applicant]
CN 103142304A · 2013 [cited by applicant]
CN 202982207U · 2013 [cited by applicant]
CN 103519887A · 2014 [cited by applicant]
CN 103908334A · 2014 [cited by applicant]
CN 103908336A · 2014 [cited by applicant]
CN 106994044A · 2017 [cited by applicant]
CN 109589169A · 2019 [cited by applicant]
CN 111214288A · 2020 [cited by applicant]
CN 213249640U · 2021 [cited by applicant]
CN 114642501A · 2022 [cited by applicant]
EP 0467422B1 · 1997 [cited by applicant]
EP 0916360A2 · 1999 [cited by applicant]
EP 1637086A1 · 2006 [cited by applicant]
EP 1637086B1 · 2010 [cited by applicant]
EP 2380518A2 · 2011 [cited by applicant]
EP 2712567A1 · 2014 [cited by applicant]
JP 2000500363A · 2000 [cited by applicant]
JP 2002065693A · 2002 [cited by applicant]
JP 2006504473A · 2006 [cited by applicant]
JP 2008245767A · 2008 [cited by applicant]
JP 2009543607A · 2009 [cited by applicant]
JP 2011224364A · 2011 [cited by applicant]
JP 2011229920A · 2011 [cited by applicant]
JP 2013510676A · 2013 [cited by applicant]
KR 20130103763A · 2013 [cited by applicant]
KR 20140088087A · 2014 [cited by applicant]
RU 2074645C1 · 1997 [cited by applicant]
RU 2102090C1 · 1998 [cited by applicant]
RU 2503408C2 · 2014 [cited by applicant]
SU 1119663A1 · 1984 [cited by applicant]
SU 1412745A1 · 1988 [cited by applicant]
SU 1734708A1 · 1992 [cited by applicant]
WO WO9301862A1 · 1993 [cited by applicant]
WO WO9505771A1 · 1995 [cited by applicant]
WO WO9733526A2 · 1997 [cited by applicant]
WO WO9965561A1 · 1999 [cited by applicant]
WO WO0137723A2 · 2001 [cited by applicant]
WO WO0137925A2 · 2001 [cited by applicant]
WO WO2007018751A2 · 2007 [cited by applicant]
WO WO2010110785A1 · 2010 [cited by applicant]
WO WO2011075328A1 · 2011 [cited by applicant]
WO WO2011091069A1 · 2011 [cited by applicant]
WO WO2011139589A2 · 2011 [cited by applicant]
WO WO2012052920A1 · 2012 [cited by applicant]
WO WO2012052921A1 · 2012 [cited by applicant]
WO WO2012052922A1 · 2012 [cited by applicant]
WO WO2012052924A1 · 2012 [cited by applicant]
WO WO2012052926A2 · 2012 [cited by applicant]
WO WO2012052927A1 · 2012 [cited by applicant]
WO WO2012068268A2 · 2012 [cited by applicant]
WO WO2012120495A2 · 2012 [cited by applicant]
WO WO2012149341A1 · 2012 [cited by applicant]
WO WO2012149511A2 · 2012 [cited by applicant]
WO WO2012154800A1 · 2012 [cited by applicant]
WO WO2012149511A3 · 2013 [cited by applicant]
WO WO2013090848A1 · 2013 [cited by applicant]
WO WO2013111136A2 · 2013 [cited by applicant]
WO WO2013157011A2 · 2013 [cited by applicant]
WO WO2012068268A3 · 2014 [cited by applicant]
WO WO2014075415A1 · 2014 [cited by applicant]
WO WO2015193889A1 · 2015 [cited by applicant]
WO WO2016007851A1 · 2016 [cited by applicant]
WO WO2016007851A8 · 2017 [cited by applicant]
WO WO2016084081A8 · 2017 [cited by applicant]
WO WO2018173047A1 · 2018 [cited by applicant]
WO WO2018173052A1 · 2018 [cited by applicant]
WO WO2018173053A1 · 2018 [cited by applicant]
WO WO2021205450A1 · 2021 [cited by applicant]
WO WO2022269545A2 · 2022 [cited by applicant]
WO WO2023173774A1 · 2023 [cited by applicant]
Benza, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. Jul. 13, 2010;12… [cited by applicant]
Brace. Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences? Curr Probl Diagn Radiol. May-Jun. 2009;38(3):135-43. doi: 10.1067/j.cpradiol.2007.10.001. [cited by applicant]
Chen, et al. Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo. EuroIntervention. Jun. 22, 2013;9(2):269-76. doi: 10.4244/EIJV912A43. [cited by applicant]
Chen, et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery … [cited by applicant]
Chen. Pulmonary artery denervaion to treat pulmonary arterial hypertension unresponive to medication: a single-center, prospective, first-in-man PADN1 study. Nanjing First Hospital, Nanjing Medical University, Nanjing, … [cited by applicant]
Chen, SL. et al., Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervat… [cited by applicant]
Chen, SL. et al., Response to Letter Regarding Article, “Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes: Phase II Res… [cited by applicant]
Chen, SL. et al., Pericardial effusion is correlated with clinical outcome after pulmonary artery denervation for pulmonary arterial hypertension. Oncotarget. Dec. 20, 2016. doi: 10.18632/oncotarget.14031. [Epub ahead o… [cited by applicant]
Chinese application No. CN20131103141 filed Mar. 27, 2013 with English Translation. [cited by applicant]
Chinese Clinical Trial Register (ChiCTR): “First-in-Man of Pulmonary artery denervation for treatment of pulmonary artery hypertention: the PADN-1 trial” dated Apr. 6, 2012, http://www.chictr.org/en/proj/show.aspx?proj=… [cited by applicant]
Chinese Clinical Trial Register (ChiCTR): “Percutaneous pulmonary arterial denervation for treatment of chronic heart failure with secondary pulmonary hypertension” dated Nov. 2, 2012, http://www.chictr.org/en/proj/show… [cited by applicant]
Chinese Clinical Trial Register (ChiCTR): “Pulmonary Artery Denervation in Patients with Pulmonary Artery Hypertention (The PADN-2 trial): a randomised controlled trial” dated Apr. 12, 2012, http://www.chictr.org/en/pro… [cited by applicant]
Cruz, et al. Cardiopulmonary Effects Following Endoscopic Thoracic Sympathectomy . European Journal of Cardio-Thoracic Surgery, Published by Elsevier BV. (2009) 491-496. [cited by applicant]
EP15818364.0 Extended Search Report dated Mar. 9, 2018. [cited by applicant]
EP22155626.9 Extended European Search Report dated Apr. 28, 2022. [cited by applicant]
European search report and opinion dated Nov. 18, 2015 for EP Application No. 13840133. [cited by applicant]
[Exam Report—Not Search Report] European Search Report dated Nov. 16, 2016 for EP Application No. 13840133.6. [cited by applicant]
Farber, et al.Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant. Mar. 2015;34(3):362-8. doi: 10.1016/j.healun.2014.08.020. Epub Aug. 28, 2014. [cited by applicant]
Farber. Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square PEG into a round hole? Circulation. Jul. 17, 2012;126(3):258-60. doi: 10.1161/Circulationaha.112.118547. E… [cited by applicant]
Flues, et al. Cardiac and pulmonary arterial remodeling after sinoaortic denervation in normotensive rats. Auton Neurosci. Jan. 26, 2012;166(1-2):47-53. doi: 10.1016/j.autneu.2011.10.005. Epub Nov. 13, 2011. (Abstract). [cited by applicant]
Fritz, et al. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest. Feb. 1, 2013;143(2):315-23. [cited by applicant]
Frost, et al.Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Chest. Nov. 2013;144(5):1521-9. doi:… [cited by applicant]
Galie, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. Feb. 2009;30(4):394-403. doi: 10.1093/eurheartj/ehp022. Epub Jan. 20, 2009. [cited by applicant]
Galie, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European R… [cited by applicant]
Galie, et al. New treatment strategies for pulmonary arterial hypertension: hopes or hypes? J Am Coll Cardiol. Sep. 17, 2013;62(12):1101-2. doi: 10.1016/j.jacc.2013.06.032. Epub Jul. 10, 2013. [cited by applicant]
Galie, et al.Tadalafil therapy for pulmonary arterial hypertension. Circulation. Jun. 9, 2009;119(22):2894-903. doi: 10.1161/Circulationaha.108.839274. Epub May 26, 2009. [cited by applicant]
Garutti, et al. Surgical upper thoracic sympathectomy reduces arterial oxygenation during one-lung ventilation. J Cardiothorac Vasc Anesth. Oct. 2005;19(5):703-4. [cited by applicant]
Hiremath, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. Feb. 2010;29(2):137-49. … [cited by applicant]
Humbert, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. Jul. 13, 2010;122(2):156-63. doi: 10.1161/Circulationa… [cited by applicant]
International search report and written opinion dated Aug. 22, 2013 for PCT/CN2013/073338. [cited by applicant]
International search report and written opinion dated Nov. 23, 2015 for PCT/US2015/039930. [cited by applicant]
Juratsch, et al. Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature. Chest. Apr. 1980;77(4):525-30. [cited by applicant]
Lang, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction… [cited by applicant]
LSI-—Life Science Intelligence, Martin Grasse, Gradient Denervation Technologies—Pulmonary Hypertension Treatment | LSI Europe '22. Nov. 12, 2012, www.youtube.com/watch?v=Hft79H2MxUs. [cited by applicant]
McLaughlin, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. Jun. 30, 2009;54(1 Suppl):S97-107. doi: 10.1016/j.jacc.2009.04.007. [cited by applicant]
McLaughlin, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. Jul. 2004;126(1 Suppl):78S-92S. [cited by applicant]
McLaughlin, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. Dec. 1, 2006;174(11):1257-63. Epub Aug. 31, 2006. [cited by applicant]
Mereles, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. Oct. 3, 2006;114(14):1482-9. Epub Sep. 18, 2006. [cited by applicant]
Naeije, et al. Pulmonary vascular responses to surgical chemodenervation and chemical sympathectomy in dogs. J Appl Physiol (1985). Jan. 1989;66(1):42-50. (Abstract). [cited by applicant]
Notice of Allowance dated Mar. 26, 2021 for U.S. Appl. No. 15/873,721. [cited by applicant]
Notice of Allowance dated Jun. 29, 2021 for U.S. Appl. No. 15/873,721. [cited by applicant]
Notice of Allowance dated Jul. 15, 2020 for U.S. Appl. No. 15/228,358. [cited by applicant]
Notice of allowance dated Aug. 16, 2016 for U.S. Appl. No. 14/672,021. [cited by applicant]
Notice of Allowance dated Sep. 11, 2017 for U.S. Appl. No. 14/672,010. [cited by applicant]
Notice of Allowance dated Sep. 14, 2017 for U.S. Appl. No. 14/672,021. [cited by applicant]
Notice of Allowance dated Sep. 19, 2017 and Sep. 7, 2017 for U.S. Appl. No. 14/666,214. [cited by applicant]
Notice of Allowance dated Sep. 22, 2017 for U.S. Appl. No. 14/672,021. [cited by applicant]
Notice of Allowance dated Sep. 24, 2019 for U.S. Appl. No. 15/228,358. [cited by applicant]
Notice of Allowance dated Oct. 13, 2017 for U.S. Appl. No. 14/672,021. [cited by applicant]
Notice of Allowance dated Oct. 13, 2017 for U.S. Appl. No. 14/672,010. [cited by applicant]
Notice of Allowance dated Oct. 13, 2017 for U.S. Appl. No. 14/666,214. [cited by applicant]
Notice of Allowance dated Oct. 18, 2017 for U.S. Appl. No. 14/672,013. [cited by applicant]
Notice of Allowance dated Nov. 2, 2017 for U.S. Appl. No. 14/672,013. [cited by applicant]
Notice of allowance dated Nov. 22, 2017 for U.S. Appl. No. 14/672,021. [cited by applicant]
Notice of Allowance dated Dec. 11, 2017 for U.S. Appl. No. 14/672,013. [cited by applicant]
Odero, et al. Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: the surgical supraclavicular approach to cervicothoracic sympathectomy. Heart Rhythm. Aug. 2010;7(8):1161-5. doi: 10… [cited by applicant]
Office action dated Jan. 5, 2015 for U.S. Appl. No. 14/530,588. [cited by applicant]
Office action dated Jan. 21, 2016 for U.S. Appl. No. 14/672,021. [cited by applicant]
Office action dated Feb. 4, 2016 for U.S. Appl. No. 14/079,230. [cited by applicant]
Office action dated Feb. 26, 2016 for U.S. Appl. No. 14/672,013. [cited by applicant]
Office action dated May 28, 2019 for U.S. Appl. No. 15/228,358. [cited by applicant]
Office action dated Jul. 14, 2015 for U.S. Appl. No. 14/666,214. [cited by applicant]
Office action dated Jul. 31, 2015 for U.S. Appl. No. 14/530,588. [cited by applicant]
Office action dated Aug. 5, 2015 for U.S. Appl. No. 14/672,010. [cited by applicant]
Office Action dated Aug. 31, 2017 for U.S. Appl. No. 14/672,013. [cited by applicant]
Office action dated Sep. 15, 2015 for U.S. Appl. No. 14/672,021. [cited by applicant]
Office action dated Oct. 8, 2015 for U.S. Appl. No. 14/672,013. [cited by applicant]
Office Action dated Oct. 21, 2016 for U.S. Appl. No. 14/530,588. [cited by applicant]
Office action dated Oct. 28, 2015 for U.S. Appl. No. 14/666,214. [cited by applicant]
Office action dated Dec. 9, 2020 for U.S. Appl. No. 15/873,721. [cited by applicant]
Office action dated Dec. 21, 2015 for U.S. Appl. No. 14/672,010. [cited by applicant]
Ommen, et al. Assessment of right atrial pressure with 2-dimensional and Doppler echocardiography: a simultaneous catheterization and echocardiographic study. Mayo Clin Proc. Jan. 2000;75(1):24-9. [cited by applicant]
Pokushalov, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J A… [cited by applicant]
Savarese, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. Sep. 25, 2012;60(13):1192-201. … [cited by applicant]
SG10201800251Y Search Report and Written Opinion dated Jan. 20, 2022. [cited by applicant]
Tei, et al. Noninvasive Doppler-derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterization measurements. J Am Soc Echocardiogr. Mar. 1997;10(2):169-78. [cited by applicant]
Zhang, H. et al., Pulmonary artery denervation for treatment of a patient with pulmonary hypertension secondary to left heart disease.Pulm Circ. Jun. 2016;6(2):240-3. doi: 10.1086/685550. [cited by applicant]
Zhang, H. et al., Pulmonary Artery Denervation Significantly Increases 6-Min Walk Distance for Patients With Combined Pre- and Post-Capillary Pulmonary Hypertension Associated With Left Heart Failure. JACC: Cardiovascul… [cited by applicant]
Zhang, YJ. et al., Pulmonary arterial hypertension: pharmacologic therapies and potential pulmonary artery denervation treatment. EuroIntervention. May 2013;9 Suppl R:R149-54. doi: 10.4244/EIJV9SRA25. Review. [cited by applicant]
Zhou, et al. Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline. JACC Cardiovasc Interv. Dec. 28, 2015;8(15):2013-2… [cited by applicant]
U.S. Appl. No. 18/203,726 Notice of Allowance dated May 8, 2024. [cited by applicant]
U.S. Appl. No. 18/203,726 Office Action dated Feb. 12, 2024. [cited by applicant]